Periorbital cellulitisMANAGEMENT

INFECTIOUS DISEASE PRESENTATIONS · 12 SECTIONS

⚲

484 items

☷ Legend

01Approach to the Critical Patient/attcp37

Immediate priorities

›Stabilization and time-critical threats

›Airway compromise concerns

›Facial trauma with airway risk

›Anaphylaxis or angioedema mimics

›Sepsis physiology

›Hypotension

›Altered mental status

›Vision-threatening infection risk

›Orbital cellulitis features

›Intracranial extension features

Rapid distinction preseptal vs orbital

›Orbital involvement screen

›Pain with extraocular movements

›Orbital cellulitis until proven otherwise

›Imaging trigger when present

›Ophthalmoplegia or restricted motility

›High-risk for orbital compartment processes

›Urgent ophthalmology involvement

›Proptosis

›Orbital cellulitis or abscess consideration

›Emergent imaging and IV antibiotics

›Decreased visual acuity or color desaturation

›Optic nerve compromise concern

›Immediate escalation pathway

›Relative afferent pupillary defect

›Post-septal pathology concern

›Emergent specialist evaluation

Early escalation and consultation

›Team activation and consults

›Ophthalmology consult criteria

›Any orbital signs

›Vision change

›Uncertain exam reliability

›ENT consult criteria

›Sinusitis with severe symptoms

›Suspected subperiosteal abscess

›Transfer criteria

›Pediatric patient needing specialty coverage

›Lack of CT or ophthalmology availability

02History/hx42

Symptom characterization

›Presenting syndrome

›Eyelid swelling and erythema

›Unilateral predominance

›Rapid progression timeline

›Pain pattern

›Eyelid tenderness

›Pain with eye movement

›Visual symptoms

›Blurry vision

›Diplopia

›Systemic symptoms

›Fever

›Malaise

Source and risk factors

›Predisposing sources

›Recent upper respiratory infection

›Sinus symptoms

›Purulent nasal discharge

›Local skin disruption

›Insect bite

›Facial abrasion or laceration

›Ocular surface infection history

›Conjunctivitis

›Hordeolum or chalazion

›Dental infection history

›Maxillary tooth pain

›Recent dental procedure

›Trauma exposures

›Orbital fracture concern

›Foreign body concern

›Host factors

›Diabetes mellitus

›Increased severe infection risk

›Consider broader coverage

›Immunocompromise

›Neutropenia

›Chronic steroids or biologics

›MRSA risk

›Prior MRSA infection or colonization

›Close contact outbreaks

›Vaccination status

›Incomplete Hib immunization

›Incomplete pneumococcal immunization

03Physical Exam/exam42

Eye and periocular exam

›Focused ocular assessment

›Visual acuity

›Baseline comparison if known

›Any decrease as escalation trigger

›Pupils

›Relative afferent pupillary defect

›Anisocoria pattern

›Extraocular movements

›Pain with movement

›Restriction pattern

›Proptosis assessment

›Globe position asymmetry

›Resistance to retropulsion if assessed

›Conjunctiva and cornea

›Chemosis

›Corneal staining when indicated

›Eyelids

›Diffuse erythema and warmth

›Fluctuance suggesting abscess

General and head and neck exam

›Associated infection evaluation

›Vital signs

›Fever pattern

›Tachycardia

›Sinus and nasal exam

›Facial sinus tenderness

›Purulent nasal drainage

›Oral and dental exam

›Gingival swelling

›Dental caries or abscess signs

›Skin exam

›Impetigo lesions

›Periorbital trauma entry point

PITFALLS

›Common diagnostic traps

›Orbital cellulitis misclassified as periorbital cellulitis

›Subtle motility pain early in disease

›Limited exam in young children

›Allergic edema mimicking infection

›Itching prominence

›Bilateral symmetry

›Herpes zoster ophthalmicus missed

›V1 dermatomal rash

›Hutchinson sign

04Differential Diagnosis/ddx42

Vision-threatening and time-sensitive causes

›Critical ocular infections and complications

›Orbital cellulitis

›ICD-10 H05.0

›Post-septal signs present

›Subperiosteal abscess

›SNOMED CT orbital subperiosteal abscess concept

›Sinusitis association

›Orbital abscess

›SNOMED CT orbital abscess concept

›Severe proptosis or ophthalmoplegia

›Cavernous sinus thrombosis

›ICD-10 I67.6

›Cranial nerve deficits

›Necrotizing soft tissue infection

›ICD-10 M72.6

›Disproportionate pain or skin necrosis

Common mimics and alternative diagnoses

›Non-postseptal mimics

›Allergic contact dermatitis

›Itching

›New topical exposure

›Angioedema

›Rapid swelling

›Urticaria or airway symptoms

›Hordeolum or chalazion

›Focal eyelid nodule

›Localized tenderness

›Dacryocystitis

›Medial canthus swelling

›Nasolacrimal reflux

›Herpes simplex eyelid infection

›Vesicles

›Recurrent history

›Herpes zoster ophthalmicus

›V1 rash

›Neuropathic pain

›Trauma-related entities

›Preseptal hematoma

›Clear trauma mechanism

›Afebrile state

›Orbital fracture with entrapment

›Diplopia

›EOM restriction without infectious signs

05Laboratory Tests/lt24

Core labs when systemic illness or admission likelihood

›Baseline and severity assessment

›Complete blood count for systemic infection

›Leukocytosis supportive but non-specific

›Normal count does not exclude orbital disease

›C-reactive protein for severity trend support

›Elevated values support bacterial process

›Trending useful when inpatient

›Basic metabolic panel for IV therapy planning

›Renal function for dosing

›Electrolytes for dehydration or sepsis

Microbiology

›Pathogen identification when feasible

›Blood cultures for toxic appearance or sepsis physiology

›Low yield in uncomplicated cases

›Higher yield in severe pediatric cases

›Purulent drainage culture if abscess or wound

›MRSA detection for targeted therapy

›Avoid superficial swab of intact skin

Additional labs in special contexts

›Risk-tailored testing

›Serum glucose for diabetes and severe infection risk

›Hyperglycemia associated with worse outcomes

›Treatment adjustment implications

›Lactate for suspected sepsis

›Elevated level supports hypoperfusion

›Serial measurement for resuscitation response

06Diagnostic Tests/dt41

Scoring Systems

›Classification and severity frameworks

›Chandler classification for orbital complications of sinusitis

›Group 1 preseptal cellulitis

›Group 2 orbital cellulitis

›Group 3 subperiosteal abscess

›Group 4 orbital abscess

›Group 5 cavernous sinus thrombosis

›Clinical orbit risk features bundle

›Pain with extraocular movements

›Ophthalmoplegia

›Proptosis

›Decreased visual acuity

MRI

›MRI orbit and brain considerations

›Indications

›Suspected intracranial complication

›Cavernous sinus thrombosis concern

›Advantages

›Superior soft tissue and intracranial detail

›Better venous sinus evaluation with MRV

›Limitations

›Time and sedation barriers in pediatrics

›Limited availability in emergent settings

›CT orbits and sinuses with IV contrast

›Indications

›Any orbital signs

›Inability to perform reliable eye exam

›Failure of appropriate antibiotics

›Key findings

›Postseptal fat stranding

›Subperiosteal fluid collection

›Orbital abscess

›Interpretation pearls

›Normal CT does not fully exclude early orbital cellulitis

›Sinus opacification as common source clue

Ultrasound

›Point-of-care ultrasound applications

›Eyelid or facial soft tissue assessment

›Abscess vs cellulitis differentiation in superficial tissue

›Guidance for drainage planning when appropriate

›Ocular ultrasound precautions

›Avoid if globe rupture concern

›Consider for optic nerve sheath diameter only in select contexts

07Disposition/dispo30

Level of care decisions

›Admission criteria

›Orbital signs present

›IV antibiotics

›Specialist evaluation

›Toxic appearance or sepsis physiology

›Parenteral therapy

›Close monitoring

›Immunocompromised host

›Broader coverage

›Lower threshold for imaging

›Age-related risk

›Infants and young children with unreliable exam

›Social barriers to follow-up

›Outpatient criteria

›No orbital signs

›Normal visual acuity

›Full painless extraocular movements

›Mild to moderate localized findings

›No fluctuance requiring procedure

›Stable vital signs

›Reliable follow-up within 24 to 48 hours

›Recheck plan documented

›Clear return precautions

Transfer criteria

›Higher level of care indications

›Suspected abscess requiring surgical capability

›Subperiosteal abscess concern

›Orbital abscess concern

›Need for pediatric subspecialty support

›Ophthalmology unavailable

›ENT unavailable

08Treatment/t119

Initial strategy and targets

›Management pathway

›Preseptal cellulitis without orbital signs

›Oral antibiotics when mild and reliable follow-up

›IV antibiotics when moderate to severe

›Any orbital signs

›IV antibiotics immediately

›Imaging and specialty consultation

›Source control considerations

›Drainable abscess evaluation

›Sinus disease management coordination

Oral antibiotic regimens

›Outpatient antibiotics

›Amoxicillin clavulanate PO

›Adult dosing options

›875 mg twice daily

›500 mg three times daily

›Pediatric dosing

›45 mg/kg/day divided twice daily as amoxicillin component

›High-dose 90 mg/kg/day divided twice daily when severe sinusitis features

›Coverage targets

›Streptococci

›MSSA

›Anaerobes from sinus sources

›Cephalexin PO for skin-source features

›Adult dosing

›500 mg four times daily

›1 g three times daily

›Pediatric dosing

›25 to 50 mg/kg/day divided 3 to 4 doses

›Higher range for moderate severity

›Coverage targets

›Streptococci

›MSSA

›MRSA-active add-on when risk or purulence

›Clindamycin PO

›Adult dosing

›300 to 450 mg three times daily

›600 mg three times daily for severe infection

›Pediatric dosing

›20 to 30 mg/kg/day divided 3 doses

›Max 450 mg per dose commonly used

›Notes

›Provides streptococcal coverage

›Local resistance considerations

›Trimethoprim sulfamethoxazole PO

›Adult dosing

›1 to 2 double-strength tablets twice daily

›Double-strength tablet 160 mg TMP component

›Pediatric dosing

›8 to 12 mg/kg/day TMP component divided twice daily

›Max dosing per local protocol

›Combination need

›Add beta-lactam for streptococcal coverage

›Pair with amoxicillin clavulanate or cephalexin

›Doxycycline PO for age-appropriate patients

›Adult dosing

›100 mg twice daily

›Avoid in pregnancy

›Pediatric restriction

›Avoid under age 8 years

›Alternative agents preferred

IV antibiotic regimens

›Inpatient antibiotics

›Ampicillin sulbactam IV

›Adult dosing

›3 g every 6 hours

›Renal adjustment when indicated

›Pediatric dosing

›50 mg/kg per dose ampicillin component every 6 hours

›Max 2 g ampicillin component per dose commonly used

›Coverage targets

›Streptococci

›MSSA

›Anaerobes

›Ceftriaxone IV plus metronidazole IV for sinus and intracranial concern patterns

›Ceftriaxone dosing

›Adult 2 g daily

›Pediatric 50 mg/kg daily to twice daily per severity

›Metronidazole dosing

›Adult 500 mg every 8 hours

›Pediatric 7.5 mg/kg every 6 hours

›Rationale

›Gram-negative coverage

›Anaerobic coverage

›Vancomycin IV add-on for MRSA risk or severe infection

›Adult dosing

›15 to 20 mg/kg per dose every 8 to 12 hours

›Trough or AUC-guided monitoring per local protocol

›Pediatric dosing

›15 mg/kg per dose every 6 hours commonly used

›Monitoring for nephrotoxicity

›Coverage targets

›MRSA

›Resistant gram-positive organisms

›Clindamycin IV option when beta-lactam allergy

›Adult dosing

›600 to 900 mg every 8 hours

›Monitor for C difficile risk

›Pediatric dosing

›10 mg/kg per dose every 8 hours

›Max 900 mg per dose commonly used

Supportive care and adjuncts

›Symptom and complication management

›Analgesia

›Acetaminophen dosing per weight

›NSAID use when no contraindications

›Hydration and perfusion support

›Oral hydration when outpatient

›IV fluids when sepsis physiology

›Ophthalmic surface protection when exposure risk

›Lubricating ointment

›Moisture chamber in severe edema

Procedure and surgical pathways

›Source control and operative considerations

›Abscess drainage indications

›Fluctuant eyelid abscess

›Failure to improve on appropriate antibiotics

›Subperiosteal abscess management collaboration

›Ophthalmology involvement

›ENT involvement

›Orbital compartment syndrome concern

›Rapid vision decline

›Proptosis with tense orbit

09Special Populations/sp33

Pregnancy

›Pregnancy-specific considerations

›Antibiotic selection

›Avoid doxycycline

›Beta-lactams preferred when appropriate

›Imaging considerations

›MRI preference when intracranial concern and feasible

›CT risk-benefit when vision-threatening suspicion

›Severity threshold

›Lower threshold for admission with systemic illness

›Maternal sepsis implications

Geriatric

›Older adult considerations

›Atypical presentation

›Blunted fever response

›Subtle mental status change

›Medication safety

›Renal dosing adjustments

›Drug-drug interaction review

›Complication risk

›Higher necrotizing infection risk in diabetes

›Lower threshold for imaging when exam limited

Pediatrics

›Pediatric considerations

›Exam reliability limitations

›Pain with EOM hard to elicit

›Visual acuity assessment challenges

›Vaccination status relevance

›Hib risk when unimmunized

›Pneumococcal disease patterns

›Admission threshold

›Young age with moderate swelling

›Inability to ensure 24-hour follow-up

›Weight-based dosing safety

›Max dose limits awareness

›Concentration and formulation checks

10Background/b31

Epidemiology

›Population patterns

›Common pediatric facial infection presentation

›Sinusitis as frequent antecedent

›Skin trauma as frequent antecedent

›Seasonal clustering

›Higher incidence during viral URI seasons

›Association with sinus infections

›Microbiology patterns

›Streptococcus species common

›Staphylococcus aureus common

Pathophysiology

›Anatomic and mechanistic concepts

›Orbital septum as boundary

›Preseptal infection confined anterior to septum

›Postseptal infection involving orbit structures

›Spread pathways

›Contiguous spread from sinuses

›Hematogenous spread in bacteremia

›Complication mechanisms

›Subperiosteal abscess from ethmoid sinusitis

›Cavernous sinus thrombosis via venous drainage

Therapeutic Considerations

›Treatment rationale

›Early antibiotics to prevent postseptal progression

›Lower threshold for IV therapy when high risk

›Close reassessment within 24 to 48 hours

›Empiric coverage targets

›Streptococci coverage baseline

›MSSA coverage baseline

›MRSA coverage when risk factors present

›Imaging timing

›Immediate imaging when orbital signs present

›Deferred imaging when classic mild preseptal and reliable follow-up

11Patient Discharge Instructions/pdi22

copy discharge instructions

›Discharge instructions

›Diagnosis explanation

›Infection of eyelid tissues in front of the eye socket

›Different from deeper orbital infection that can threaten vision

›Medication plan

›Antibiotics exactly as prescribed until finished

›Do not skip doses

›Symptom care

›Warm compresses to eyelid for comfort

›Acetaminophen or ibuprofen for pain if allowed

›Follow-up plan

›Recheck within 24 to 48 hours

›Earlier recheck if symptoms worsen

›Return to emergency immediately for any of the following

›Pain when moving the eye

›Double vision

›Trouble moving the eye

›Bulging eye appearance

›New or worsening vision changes

›Severe headache

›High fever or worsening illness

›Increasing swelling despite antibiotics

12References/r21

Clinical guidelines and evidence sources

›Guideline and reference set

›Infectious Diseases Society of America skin and soft tissue infection guidance

›Empiric MRSA coverage principles in purulent cellulitis settings

›Duration and reassessment principles

›American Academy of Pediatrics Red Book guidance

›Pediatric facial and periorbital infection antibiotic options

›Vaccine-era organism considerations

›American Academy of Ophthalmology clinical education resources

›Orbital cellulitis warning signs

›Imaging triggers and consult pathways

›Otolaryngology guidance for complicated sinusitis

›Subperiosteal abscess management pathways

›Surgical consideration criteria

Coding and terminology

›Medical coding references

›ICD-10 periorbital cellulitis

›L03.213 cellulitis of right periorbital region

›L03.214 cellulitis of left periorbital region

›L03.219 cellulitis of unspecified periorbital region

›ICD-10 orbital cellulitis

›H05.0 orbital cellulitis

›Postseptal infection term alignment

Learn More: Periorbital cellulitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.